Abstract: The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor.

Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.

Abstract: The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment of neuropathic pain. The invention contemplates to aryloxy-substituted amines, as sodium channel blockers or modulators. In further embodiments, the invention also relates to compounds which may advantageously have dual sodium channel blocker/modulating and antioxidative (free-radical scavenging) effects. Methods for their manufacture and compositions containing the compounds are also contemplated.

Abstract: The present invention relates to biologically active single chain relaxin polypeptides comprising a relaxin B chain derived from relaxin-3, the polypeptides being truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain. Typically the single chain relaxin polypeptides are antagonists of the RXFP3 receptor, and in some embodiments are selective antagonists of the RXFP3 receptor.

Abstract: The present invention relates to biologically active relaxin polypeptides comprising a relaxin A chain and a B chain derived from a relaxin superfamily member, wherein the A chain comprises no intra-chain disulphide bonds. In particular embodiments the modified polypeptides comprise relaxin-3 derived A and B chains, and truncations of the A and/or B chains from the N-termini and/or C-termini. In particular embodiments the polypeptides of the invention are selective agonists or antagonists of the RXFP3 receptor.

Abstract: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Abstract: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Abstract: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Abstract: This invention relates to a method of assaying a compound for its ability to modulate an ion channel or receptor type, the method comprising: a) providing a dynamic clamp in electrical contact with a biological cell (or part thereof) in which one or more ion channel or receptor types for providing a waveform are functional and in which one or more ion channel or receptor types for providing a waveform are either not present or not functional; b) causing the dynamic clamp to apply a signal simulating the function of at least one of the one or more ion channel or receptor types that are either not present or not functional in the biological cell (or part thereof) based on modulation of the ion channel or receptor types that are functional in the biological cell (or part thereof) to thereby provide the waveform at the biological cell (or part thereof); c) exposing at least one of the one or more functional ion channel or receptor types to a compound; and d) detecting modulation of the waveform at the biological

Abstract: Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts have uses in the areas of pharmaceuticals, nutraceutical, and veterinary applications.

Abstract: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Abstract: Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts have uses in the areas of pharmaceuticals, nutraceutical, and veterinary applications.

Abstract: Treatment, detection and monitoring of disease of the nervous system, especially trauma or hypoxia, in particular in the central nervous system and the eye by up-regulation or increasing levels of Ndfip1 (also known as Nedd4-WW Domain Binding Protein 5 or N4WBP5). Prophylaxis of such conditions in pre-term infants, coronary artery bypass graft, chemotherapy, tumor irradiation and other patients.

Abstract: The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions, regulating cellular glucose uptake and homeostasis, inducing labour and lactation, and other disorders or conditions wherein excessive or undesirable IRAP activity is implicated.

Abstract: Monomeric, cyclic peptide analogues of relaxin superfamily proteins, based on B-chains of relaxin superfamily proteins, and methods of making them, are described, as well as pharmaceutical compositions containing them and methods of utilising them.

Abstract: A method for treating cardiac fibrosis resulting from injury of a mammalian heart is described comprising the step of contacting a therapeutically effective amount of relaxin and/or an LGR7 activating agent with cardiac cells following the injury in an amount sufficient to reduce the fibrosis. Also described are methods for protecting the heart following an ischemic event, inhibiting the proliferation of activated fibroblasts and antagonising collagen secretion or deposition in a mammalian heart.

Abstract: The invention relates to neuroactive peptides or analogues thereof, having at least one of the biological activities of angiotensin IV, and which comprise the sequence Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe, to methods of modulating neuronal activity, and to pharmaceutical composition thereof.

Abstract: A method for determining the presence and location in animal or plant tissue of a specific polynucleotide population comprising: (a) preparing a section of the tissue to be examined; (b) contacting the tissue section under hybridization conditions with a synthetic, labelled oligonucleotide probe which is complementary to a representative portion of the target polynucleotide; (c) removing unhybridized probe material from the tissue section; and (d) detecting or identifying the locations in the tissue section where labelling or hybridization of the labelled probe has occurred. A diagnostic kit for use in performance of the above method is also disclosed.

Abstract: This invention relates to novel oligonucleotide-polyamide conjugates preferably having a free 3' hydroxl moiety, and wherein the polyamide is coupled to the oglionucleotide through its carboxyl terminus. A nucleotide polymer conjugate of the formula (I): Nu--NUC--C.dbd.C--X.sup.1 --NH--X.sup.2 --X.sup.3 where X.sup.1 is an unsubstituted or substituted C.sub.1 -C.sub.10 alkylene group, in which one or more carbons may optionally be replaced by --NH--, --O-- or --S--; X.sup.2 is a bond, or an unsubstituted or substituted C.sub.1 -C.sub.20 alkylene group, in which one or more carbons may optionally be replaced by --NH--, --O-- or --S--; the optional substituents in X.sup.1 or X.sup.2 are selected from a variety of groups; X.sup.3 is an amino acid or a polyamide linked via its carboxy terminus; NUC is a nucleoside group of any one of formulas (a), (b), (c), (d) where.fwdarw.indicates the bond to the --C--C-- group in formula (I), and X.sup.

Abstract: Methods are provided for the hybridization of a target polynucleotide with a conjugate. The conjugate comprises an oligonucleotide covalently bound to a linker that is covalently bound to an amino acid or a polyamide. The oligonucleotide portion of the conjugate comprises an anti-sense sequence which is complementary to and hybridizes with the target polynucleotide. The method is useful for detecting the presence of viral or bacterial target polynucleotides.